◈ Nootpedia
Compact view
Research pass: thorough Pharmaceutical · Oral WATCH-LIST HIGH

Ketamine

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict WATCH-LIST HIGH

For Dylan-archetype (20yo, brain-priority, MMA, NO current depression), ketamine is a hold-for-trigger compound — not daily, not prophylactic, not for cognitive enhancement. The TRD evidence is A-tier and the rapid-antidepressant mechanism is genuine (Berman 2000 → Krystal/Sanacora replications → Spravato approval 2019), but Dylan has no depression and no acute TBI requiring ICU sedation. The TBI-protection angle is theoretically attractive (NMDA glutamate excitotoxicity is a major secondary-injury mechanism in concussion) but the human data is mixed-to-neutral, the clinical trials are in severe TBI/ICU settings, and the protective effect requires acute administration immediately post-injury — not a chronic biohacker tool. Chronic recreational/at-home use carries real risks: ketamine bladder (interstitial cystitis, often irreversible), cognitive blunting in heavy users, fast tolerance, and dependence potential despite earlier "non-addictive" framing. Verdict would upgrade to OPTIONAL-ADD-PRN if Dylan develops treatment-resistant depression that fails standard SSRIs/SNRIs/bupropion (then KAP via licensed clinic, 6-session induction, monthly maintenance). Verdict would upgrade to STRONG-CANDIDATE for a different archetype (current TRD patient who has failed two antidepressants). Verdict would drop to SKIP-PERMANENT if Dylan demonstrated any compulsive substance use pattern, history of dissociative misuse, or urinary symptoms.

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload, no current depression (Dylan-archetype)
    WATCH-LIST

    No daily protocol. No prophylactic protocol. The TBI-protection rationale is mechanism-only and doesn't survive the lack of human RCT data and the acute-window requirement. Hold for triggers: emergent TRD failing first-line meds (then licensed IV clinic or Spravato), KAP for major trauma processing. Avoid all unsupervised/illicit/at-home use.

  • 30-50, executive maintenance, no depression
    WATCH-LIST

    Same analysis as Dylan-archetype. Trigger-based deployment only.

  • 50+, mild cognitive decline, no depression
    SKIP-FOR-NOW

    Ketamine has not shown benefit in mild cognitive decline absent depression. Different compounds (memantine, donepezil, lifestyle) are first-line.

  • Treatment-resistant depression (any age, after ≥2 failed antidepressant trials)
    STRONG-CANDIDATE

    This is the indication where ketamine is genuinely transformative. IV ketamine 6-session induction or Spravato is the most-validated path. NNT ~3-5 for response. Combined with continued oral antidepressant per FDA labeling.

  • Major depression with acute suicidal ideation
    STRONG-CANDIDATE

    Spravato + standard care is FDA-approved for this indication (ASPIRE trials, 2020). IV ketamine off-label is also widely used. Rapid suicidal-ideation reduction within hours.

  • PTSD (moderate-severe, treatment-refractory)
    OPTIONAL-ADD

    via KAP at licensed clinic. B-tier evidence accumulating. KAP framework with therapist preferred over standalone infusions.

  • CRPS / refractory neuropathic pain
    STRONG-CANDIDATE

    for IV infusion at pain clinic. A-tier evidence. ASRA 2018 guideline endorsement.

  • Anxiety-prone (no depression)
    NEUTRAL-

    Ketamine's acute anxiolytic effects are not durable, and the dissociation may worsen anxiety in some users. First-line anxiety treatments preferred.

  • High athletic load, tested status
    WATCH-LIST

    Ketamine is on the WADA Prohibited List for in-competition use (Section S6 stimulants/anesthetics). Not relevant for Dylan's untested status, but the bladder risk and cognitive cost remain concerns.

  • Sleep-disordered
    NEUTRAL

    Not a sleep tool. Some evidence of sleep architecture disruption.

  • Recovery-focused (post-injury, post-illness)
    NEUTRAL

    No specific role outside the TRD/KAP indications and acute pain control.

  • Strength/anabolic-focused
    NEUTRAL

    No anabolic effects; not relevant.

  • Substance use disorder (alcohol, cocaine)
    OPTIONAL-ADD

    via licensed program with motivational therapy. B-tier emerging evidence (Dakwar et al.). Not first-line; standard SUD treatment is.

▸ Subjective experience (deep)

Critical caveat: Ketamine is a felt-effect compound at all clinically meaningful doses. Even sub-anesthetic infusions produce notable dissociation, perceptual changes, and altered cognition during the dose. This is not memantine.

Sub-anesthetic IV (0.5 mg/kg over 40 min — TRD protocol):

  • Onset within 1-2 min of infusion start. Floating sensation, body-distortion (limbs feel detached, swollen, or absent). Mild visual changes — patterns on ceiling, slight color saturation shifts. Time distortion (subjectively the 40-min infusion can feel much shorter or much longer).
  • Peak 15-25 min in. Dissociation: "watching myself from outside," "thoughts feel distant," "self/non-self boundary loosens." Mild euphoria common but not universal — some users describe peaceful detachment, others mild anxiety. Speech often becomes effortful or paused.
  • Taper 25-40 min. Effects fade as infusion ends. Most users functionally recovered within 30-60 min post-infusion, fully back to baseline 1-2 hr.
  • Antidepressant effect: typically detectable within 4-24 hr post-infusion. Mood lift, reduced rumination, "weight off chest." Often described as "the depression door is suddenly open" or "I can see how I should feel again." Effect peaks 24-72 hr, wanes over 1-2 weeks.

Intranasal esketamine (Spravato, 56-84 mg in clinic):

  • Similar dissociation profile to IV but typically less intense and more variable in onset (5-30 min). Patient remains in clinic for 2-hr post-administration monitoring (REMS requirement). Same antidepressant time-course as IV ketamine.

IM (1-2 mg/kg — clinical / KAP):

  • Similar to IV but more rapid full-onset (3-5 min) and more abrupt offset. Sometimes preferred for KAP because the experience is more compressed and structured.

Sublingual lozenge / RDT (100-300 mg held in mouth 10-15 min — at-home telehealth):

  • More variable. Slow onset (15-45 min), mild-to-moderate dissociation at 100 mg, more pronounced at 200-300 mg. Duration 2-4 hr including comedown. Subjectively softer than IV. Variability is high — same dose can produce different experiences day-to-day depending on absorption.

Recreational anesthetic-tier dose (~150-250 mg IM, "K-hole"):

  • Full dissociative anesthesia. Loss of body awareness, often loss of conscious memory of the experience. Visual hallucinations, breakthrough dream-like content. Not a therapeutic dose — recreational/exploratory. Risk profile higher.

Cognitive effects:

  • During the dose: working memory and executive function are impaired. Don't drive. Don't make decisions.
  • Post-dose recovery: most users feel fully cognitively normal within 2-4 hr.
  • Days following a single therapeutic dose: most users describe improved cognitive flexibility, less rumination, better mood — driven by the BDNF/synaptogenesis cascade.
  • Chronic heavy use: measurable cognitive impairment in working memory, episodic memory, and executive function (Morgan & Curran 2012, multiple replications). Reverses partially on cessation.

Ketamine-assisted psychotherapy (KAP) framing: The therapeutic context matters enormously. KAP protocols pair the dose with a therapist (or therapist-supervised setting), preparation session before, and integration session after. This is the clinically-validated framework. "At-home microdose lozenge" via telehealth platforms has weaker outcome data and is the emergent commercial frontier — not yet matched by rigorous trials.

Variability: Very high. Set, setting, prior dissociative experience, dose form, recent use, baseline mood state, and individual NMDA-receptor variation all influence the experience substantially. The same dose can produce healing for one user and a distressing experience for another.

▸ Tolerance + cycling deep dive

  • Tolerance buildup: Fast. Tachyphylaxis develops within days-to-weeks of regular dosing. Recreational users often double or triple dose within months. Clinical protocols (weekly to monthly) appear to maintain effect over years in responders, but the antidepressant effect itself is a phasic re-induction, not a steady-state pharmacological tone.

  • Recommended cycle: Clinical TRD: 6-session induction over 2-3 weeks, then maintenance based on symptom return — typically every 1-4 weeks for responders. No daily dosing protocol exists for legitimate clinical use.

  • Reset protocol if needed: If tolerance manifests in chronic responders, abstinence weeks-to-months may partially restore sensitivity. No formal reset protocol.

  • Withdrawal: Mild physical withdrawal possible after very heavy chronic use (anxiety, restlessness, craving). Far less than opioid withdrawal but real. Clinical-protocol patients do not typically experience withdrawal between maintenance infusions.

▸ Stacking deep dive

Synergistic with

  • Standard antidepressants (SSRIs, SNRIs, bupropion): TRD protocols routinely combine ketamine induction with continued SSRI/SNRI (esketamine FDA approval is with an oral antidepressant). Different mechanisms — ketamine produces rapid relief while monoamine antidepressants maintain longer-term tone. Well-characterized combination safety.

  • Lamotrigine (in some bipolar/TRD protocols): May slightly attenuate ketamine's psychotomimetic effects via sodium channel modulation, sometimes used as an adjunct. Not contraindicated.

  • Therapy / psychotherapy (KAP framework): Strong synergy. The neuroplastic window after a ketamine dose (hours to days) appears to enhance therapy uptake. The Dakwar substance-use trials show this in cocaine and alcohol use disorder; KAP trials show it in PTSD.

  • Lithium (bipolar TRD): Sometimes combined cautiously. Neither is contraindicated by the other.

Avoid stacking with

  • Memantine (and other NMDA antagonists — amantadine, dextromethorphan, MK-801): Compounded NMDA blockade. Theoretical risk of additive dissociation, cognitive impairment, possible neurotoxicity at high combined exposures. Practical implication: if Dylan ever pursues ketamine therapy, memantine should be discontinued well in advance (>2 weeks for memantine washout given its 60-80 hr half-life).

  • MAOIs (selegiline at high doses, rasagiline, tranylcypromine, phenelzine): Hypertensive crisis risk via potentiation of ketamine's monoamine reuptake inhibition. Selegiline at 1-2.5 mg (Dylan's optional V5 dose) is MAO-B-selective and the risk is theoretical/minor; higher non-selective doses are a real concern.

  • High-dose serotonergic agents (tramadol, MDMA, fluoxetine + MAOI combination): Theoretical serotonin contribution; ketamine is weakly serotonergic, but the risk is generally lower than with classical serotonin syndrome triggers. SSRIs alone are routinely co-administered with ketamine in TRD protocols without serotonin syndrome.

  • Theophylline / xanthines at high doses: Lower seizure threshold; combined with ketamine's modest seizure-threshold effect, theoretical combined risk.

  • Other CNS depressants (benzodiazepines, opioids, alcohol): Additive sedation, respiratory depression at anesthetic doses. Benzodiazepines are deliberately combined with ketamine in clinical anesthesia to manage emergence dissociation — this is supervised and dose-controlled. In recreational settings the combination raises overdose risk.

  • Other stimulants (high-dose amphetamines, cocaine): Compounded sympathomimetic load → BP/HR spikes, theoretical cardiac risk.

Neutral / safe co-administration

V4/V5 stack: DHA, magnesium, citicoline, NAC, phosphatidylserine, curcumin, rhodiola, theanine, glycine/L-tryptophan, D3+K2, beta-alanine, vitamin C, creatine — none have documented ketamine interactions and most are mechanistically distinct. Bromantane — no documented interactions. Modafinil — no documented interactions; both have been used together in some TRD-with-fatigue protocols. Adamax / Semax / Selank — peptides, different pathways, no documented interactions. ALCAR, apigenin, taurine, astaxanthin — neutral. Bupropion — clinically combined with ketamine in TRD (different mechanism: NDRI vs NMDA). Naltrexone — theoretical attenuation of ketamine antidepressant effect (Williams 2018 Stanford trial); not a contraindication but a known interaction for the opioid-receptor-contribution debate.

▸ Drug interactions deep dive

  • CYP enzymes: Ketamine is metabolized primarily by CYP3A4 and CYP2B6, with minor contribution from CYP2C9. Strong CYP3A4 inhibitors (clarithromycin, ketoconazole, ritonavir, grapefruit juice in large quantities) can elevate ketamine exposure. Strong CYP3A4 inducers (rifampin, carbamazepine, St. John's Wort) reduce exposure. CYP2B6 is highly polymorphic — slow metabolizers (CYP2B6*6/*6 etc.) have substantially higher ketamine exposure (up to 2-3× plasma levels at the same dose). Dylan's 23andMe results pending June 2026 may include CYP2B6 status — if he's a slow metabolizer and ever uses ketamine, lower starting doses are warranted.

  • Modafinil: Modafinil weakly induces CYP3A4 (theoretical reduced ketamine exposure) and is a weak CYP2C19 inhibitor. Practical impact on ketamine PK is minor. No documented adverse interaction.

  • Bupropion: Bupropion is a CYP2D6 inhibitor and CYP2B6 substrate. Theoretical mild competition at CYP2B6, but bupropion's affinity is lower than ketamine's so the interaction is minor. Routinely combined in TRD.

  • Cerebrolysin / peptides: No documented interactions. Different molecular pathways.

  • Selegiline at low doses (1-2.5 mg, MAO-B selective): No clinically meaningful interaction at this dose. At higher non-selective MAO-A doses the interaction would be significant.

  • Anticoagulants: No significant interaction.

  • Contraceptives: No documented interaction.

  • Alcohol: Acute combination — additive CNS depression and dissociation; chronic alcohol use may alter CYP2B6 expression and modify ketamine metabolism. Dylan's zero-alcohol baseline makes this irrelevant.

  • Thyroid hormones: Hyperthyroidism may potentiate ketamine's sympathomimetic effects (BP, HR, dysrhythmia risk). Worth checking thyroid panel before any ketamine use.

▸ Pharmacogenomics

  • CYP2B6 polymorphisms (most actionable). *6/*6 homozygous slow metabolizers (Q172H + K262R variants) show 2-3× higher ketamine plasma exposure at the same dose. *4 carriers have intermediate exposure. About 5-10% of European-ancestry populations are *6/*6 slow metabolizers; rates are higher in some African populations. Dylan's 23andMe raw data should include rs3745274 and other CYP2B6 variants — if he ever uses ketamine, slow-metabolizer status warrants reduced starting dose.

  • CYP3A4/3A5 polymorphisms — minor impact on ketamine clearance. CYP3A5*3 (poor expressor, common in non-African populations) may slightly reduce clearance.

  • GRIN2A / GRIN2B polymorphisms — theoretical individual sensitivity to NMDA antagonism. Not clinically actionable.

  • BDNF Val66Met — Met carriers have reduced activity-dependent BDNF release, theoretically reducing ketamine antidepressant response; some clinical correlation reported but not robustly replicated.

  • OPRM1 A118G (μ-opioid receptor variant) — given the Williams 2018 naltrexone-attenuation finding, OPRM1 variants may modulate ketamine antidepressant response. Not clinically actionable yet.

  • For Dylan (23andMe results pending June 2026): The actionable flag is CYP2B6 status. If *6 homozygous, lower starting ketamine doses are warranted in any future deployment.

▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Clinical IV ketamine for TRD (off-label) Licensed psychiatry/anesthesiology clinic $400-800/infusion, $2400-4800/induction high Most-validated path. Search "ketamine infusion clinic [city]" or via American Society of Ketamine Physicians directory. Insurance rarely covers IV ketamine for depression.
Spravato (intranasal esketamine, FDA-approved TRD) Psychiatrist + REMS-certified clinic $600-900/session cash; insurance variable high Only FDA-approved form for TRD. Requires diagnosis of TRD (failure of ≥2 oral antidepressants), in-clinic 2-hr observation, REMS enrollment. Most rigorous regulatory framework.
At-home lozenge telehealth Mindbloom, Joyous, Better U, others $300-500/month medium Telehealth visit + sublingual lozenges shipped. Less rigorous than IV/IN clinical protocols. Some platforms have come under FDA/state board scrutiny. Self-administration without in-person observation.
Ketamine-assisted psychotherapy (KAP) Licensed psychiatrist + therapist team $600-1500/session high Most therapeutically rigorous for trauma/depression. Combines IM/IN ketamine with psychotherapy preparation + integration. Less common than standalone IV protocols.
US Rx via PCP (anesthesia/pain only — not depression) Anesthesiologist, pain specialist Variable high Not a depression path. Pain or anesthesia contexts only.
Illicit "K" / street ketamine Recreational supply chains Variable low Strongly not recommended. Quality unreliable, fentanyl contamination rare but documented, dose unreliable, legal risk (Schedule III).
Veterinary ketamine diversion N/A N/A N/A Not a legitimate sourcing path. Diversion is a federal offense.
Indian pharmacy / gray-market Various Variable low-medium Schedule III status makes import legally risky. Not recommended.

Cost reality check for clinical use: $2400-4800 for IV induction (6 sessions), $300-500/month for at-home lozenge maintenance, $600-900/session for Spravato. Significantly more expensive than any other compound on Dylan's V4/V5 list. Not amortizable; only relevant if a TRD trigger fires.

Recommendation for Dylan: Hold for trigger (TRD failing first-line meds, or KAP for trauma processing). When triggered, licensed clinic for IV induction or Spravato through psychiatrist. Do NOT pursue illicit, gray-market, or unsupervised at-home protocols — the bladder/cognitive/dependence risk profile is real and the supervised clinical context is what makes this drug acceptable.

▸ Biomarkers to track (deep)

  • Baseline (before any clinical ketamine deployment): Depression scale (PHQ-9, MADRS, BDI). Suicidal ideation (C-SSRS). Dissociation baseline (CADSS). BP and HR. Liver panel (AST/ALT). Urinalysis baseline. Cardiac history including BP control. CYP2B6 status if known. Substance use history. Trauma history (relevant for KAP planning).

  • During clinical induction: Pre/post-infusion BP and HR each session. Dissociation scale (CADSS) each session. Depression scale weekly. Suicidal ideation per session. Adverse effect tracking.

  • Maintenance (clinical): Depression scale at each visit. Urinary symptoms questionnaire (LUTS) every visit. Liver panel every 3-6 months. BP at each session.

  • Chronic at-home lozenge use (less rigorous oversight): Same as maintenance plus quarterly urinalysis with cytology, and immediate cessation + urology consult on any new urinary symptoms.

  • Post-treatment: Depression scale follow-up monthly. Urinary symptoms follow-up. Cognitive baseline re-check if heavy use.

▸ Controversies / open debates Live debate

  • Opioid receptor contribution to antidepressant effect (Williams 2018 vs replications). Stanford crossover trial (n=12, Am J Psychiatry) showed naltrexone pretreatment attenuated ketamine's antidepressant response. Yoon 2019 and Marton 2019 partial replications and partial non-replications. Field divided. If true, has implications for abuse liability, mechanism, and combination with opioid antagonists. Not yet clinically actionable.

  • R-ketamine vs S-ketamine. Hashimoto's group (Chiba University) has argued for years that R-ketamine (arketamine) is the superior antidepressant — longer-lasting effect, less dissociation, fewer side effects in animal models. Perception Neuroscience PCN-101 (R-ketamine) Phase 2 results (2023) showed mixed results; the field is awaiting larger trials. If R-ketamine wins out, it could replace S-ketamine for depression.

  • At-home lozenge protocols — efficacy and safety vs IV. Rapid commercial expansion (Mindbloom, Joyous, etc.) has outpaced rigorous comparison trials. Some clinicians argue at-home lozenge access democratizes a transformative treatment; others argue it bypasses essential supervision and risks bladder/dependence harm. Regulatory landscape evolving — FDA letters and state board actions in 2023-2025 indicate growing scrutiny.

  • Ketamine bladder — incidence in clinical-protocol patients vs heavy users. Heavy recreational/illicit users (>1 g/day) have a clear, often-irreversible bladder syndrome. Clinical-protocol patients (single doses weekly to monthly) appear at very low risk, but case reports exist. The honest position: dose-cumulative; supervised clinical use is much safer than chronic recreational; uncertainty about middle-frequency at-home lozenge use.

  • Long-term safety of repeat clinical infusions. Spravato and IV protocols have been used for years without major signal of cumulative harm in monitored populations, but the longest-duration data is ~5-7 years. Decades-long use is uncharacterized.

  • TBI / neuroprotection — animal vs human disconnect. Animal models show neuroprotection in acute TBI; human ICU studies show neutral safety on ICP and possibly outcome-neutral or modestly beneficial; no chronic prophylactic human RCT exists. The biohacker framing of "ketamine for TBI protection" overstates the human evidence considerably.

  • Suicidal ideation reduction — durability. Spravato ASPIRE trials demonstrated 24-hr reduction; longer-term durability requires repeat dosing. Whether ketamine genuinely reduces suicide risk over months-to-years is less clearly demonstrated than the acute reduction.

  • Brain-development concern at age 20. Animal adolescent ketamine exposure shows persistent PFC changes; human translation contested. Clinical use in TRD adolescents is increasingly common but long-term outcomes data is limited.

  • KAP psychotherapy contribution. Whether the therapy adds meaningfully on top of the pharmacological effect is empirically open. Some trials suggest yes; others suggest most of the benefit is pharmacological. The KAP framework dominates clinical trauma-processing practice nonetheless.

  • Mindbloom-style "microdose ketamine" framing. "Microdose" is a misnomer — at-home lozenge doses (100-300 mg) produce notable dissociation in most users; this is not microdosing in any rigorous sense. The framing has marketing rather than pharmacological grounding.

  • Compulsive use risk vs early "non-addictive" framing. Original 1970s-1990s literature framed ketamine as essentially non-addictive; clinical experience and the global recreational use pattern (especially Hong Kong, UK 2010s) revealed real psychological dependence and compulsive escalation in vulnerable users. The earlier framing was wrong; current framing acknowledges Schedule III-level abuse liability.

▸ Verdict change log
  • 2026-05-06 — Initial verdict: WATCH-LIST (HIGH confidence). For Dylan-archetype (20yo, brain-priority, MMA, no current depression, no acute TBI), ketamine is a hold-for-trigger compound. The TRD evidence is genuinely transformative and A-tier, but Dylan has no depression. The TBI-protection rationale is mechanistically attractive but the human evidence is mixed and the protection window requires acute hospital deployment, not chronic biohacker use. Chronic recreational/at-home use risks bladder syndrome, cognitive blunting, dependence, and persistent PFC dysregulation. Verdict would upgrade to OPTIONAL-ADD-PRN-only if Dylan develops TRD failing first-line antidepressants (then licensed clinic IV induction or Spravato). Verdict would upgrade to STRONG-CANDIDATE for a different archetype with current TRD. Verdict would drop to SKIP-PERMANENT on any sign of compulsive substance use, urinary symptoms, or dissociative misuse pattern.
▸ Open questions / gaps Open

  1. Prophylactic chronic ketamine for subconcussive impact protection — does the mechanism translate to humans? No human RCT exists. The animal data is mixed and the clinical literature is in severe TBI/ICU settings. Would change verdict if a definitive trial demonstrated chronic low-dose neuroprotection without bladder/cognitive cost.

  2. At-home lozenge long-term safety (5+ years). The commercial telehealth expansion has outpaced safety data. Bladder, cognitive, and dependence outcomes over years of weekly lozenge use are uncharacterized.

  3. R-ketamine vs S-ketamine head-to-head. PCN-101 Phase 3 results pending. If R-ketamine is genuinely cleaner, the risk/benefit may shift.

  4. Opioid-receptor contribution to antidepressant effect. Williams 2018 needs definitive replication. If true, has implications for combination strategy and abuse liability.

  5. For Dylan specifically: Does CYP2B6 status predict any individual sensitivity? Will a TBI event ever trigger an acute ketamine indication? Both N=1 questions answered only as life unfolds.

  6. TBI/concussion human RCT in awake patients. Fundamental gap. Animal data and severe-TBI ICU data don't translate to subconcussive impact in conscious athletes.

▸ Sources (full, with our context)
Back to compact view